Search results for " metabolic"

showing 10 items of 1022 documents

Glucose transporter 4 mRNA expression in subcutaneous adipose tissue of women with PCOS remains unchanged despite metformin withdrawal: is there a ce…

2021

Purpose: Metformin induces GLUT-4 mRNA expression in insulin target tissues in PCOS. It is unclear how long this impact is sustained after withdrawal of metformin. We aimed to compare the effect of metformin withdrawal on GLUT-4 mRNA expression in subcutaneous adipose tissue after prior short (ST, 1 year, N = 11) and long term (LT, at least 3 years, N = 13) treatment in obese PCOS women. Methods: At baseline and 6 months after withdrawal, biopsy of subcutaneous adipose tissue followed by quantitative PCR analysis was performed to determine GLUT-4 mRNA expression. Results: We found no time/effect differences in GLUT-4 mRNA expression in ST (2-dCt at baseline 0.42 (0.16–0.48) vs 2-dCt after 6…

medicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMrna expressionGlucose Transport Proteins FacilitativeSubcutaneous FatAdipose tissueQuantitative PCR analysisEndocrinologyInternal medicineBiopsymedicineHumansRNA MessengerAdipose tissue GLUT-4 mRNA Metformin PCOS Adipose Tissue Female Humans RNA Messenger Subcutaneous Fat Metformin Polycystic Ovary Syndromemedicine.diagnostic_testbusiness.industryInsulinGlucose transporternutritional and metabolic diseasesMetforminMetforminEndocrinologyAdipose TissueFemaleSubcutaneous adipose tissuebusinessPolycystic Ovary Syndromemedicine.drug
researchProduct

Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters.

2005

In hyperandrogenic women, several phenotypes may be observed. This includes women with classic polycystic ovary syndrome (C-PCOS), those with ovulatory (OV) PCOS, and women with idiopathic hyperandrogenism (IHA), which occurs in women with normal ovaries. Where other causes have been excluded, we categorized 290 hyperandrogenic women who were seen consecutively for this complaint between 1993 and 2004 into these three subgroups. The aim was to compare the prevalence of obesity, insulin resistance, and dyslipidemia as well as increases in C-reactive protein and homocysteine in these different phenotypes with age-matched ovulatory controls of normal weight (n = 85) and others matched for body…

medicine.medical_specialtyendocrine system diseasesHomocysteineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryBiochemistryBody Mass IndexNORMAL MENSESchemistry.chemical_compoundEndocrinologyInsulin resistanceRisk FactorsInternal medicineparasitic diseasesmedicineHumansInsulinANDROGEN EXCESSDEHYDROEPIANDROSTERONE SULFATEPLASMAbusiness.industryInsulinBiochemistry (medical)Hyperandrogenismnutritional and metabolic diseasesCholesterol LDLPOLYCYSTIC-OVARY-SYNDROMELuteinizing Hormonemedicine.diseaseObesityPolycystic ovaryfemale genital diseases and pregnancy complicationsEndocrinologyC-Reactive ProteinPhenotypechemistryCardiovascular DiseasesFemaleSENSITIVITYInsulin ResistancebusinessBody mass indexDyslipidemiaPolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct

Gestational diabetes and the metabolic syndrome: Can obesity and small, dense low density lipoproteins be key mediators of this association?

2013

Gestational diabetes mellitus (GDM) represents a condition of glucose intolerance with first appearance or recognition at the time of a pregnancy, associated with an inadequate pancreatic response to the advanced insulin resistance of the later stages of pregnancy, and accompanied by enhancing β-cell mass and secretion of insulin. Women who had GDM exhibit a higher risk for later advent of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD). Additionally, previous GDM has been proposed as independently correlated with higher risk for development of atherosclerosis in a healthy population, similar to the metabolic syndrome (MetS) and independently of the presence of established…

medicine.medical_specialtyendocrine system diseasesPharmaceutical ScienceInsulin resistancePregnancyDiabetes mellitusInternal medicineHumansMedicineObesityMetabolic SyndromePregnancybusiness.industryObstetricsnutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseaseObesityLipoproteins LDLGestational diabetesDiabetes GestationalEndocrinologyFemaleMetabolic syndromecardiovascular disease cardiovascular risk gestational diabetes mellitus metabolic syndrome small dense low-density lipoprotein type 2 diabetes mellitusbusinessPostpartum periodBiotechnology
researchProduct

The importance of diagnosing the Polycystic Ovary Syndrome

2000

The polycystic ovary syndrome (PCOS) is an extremely common disorder that occurs in 4% to 7% of women of reproductive age. Although PCOS is known to be associated with reproductive morbidity and increased risk for endometrial cancer, diagnosis is especially important because PCOS is now thought to increase metabolic and cardiovascular risks. These risks are strongly linked to insulin resistance and are compounded by the common occurrence of obesity, although insulin resistance and its associated risks are also present in nonobese women with PCOS. Women with PCOS are at increased risk for impaired glucose tolerance, type 2 diabetes mellitus, and hypertension. Cardiovascular disease is believ…

medicine.medical_specialtyendocrine system diseasesPhysiologyType 2 diabetesImpaired glucose toleranceInsulin resistanceDiabetes mellitusInternal medicineGlucose IntoleranceInternal MedicinemedicineHumansRisk factorbusiness.industryFibrinolysisnutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseObesityPolycystic ovaryLipidsfemale genital diseases and pregnancy complicationsEndocrinologyCardiovascular DiseasesFemalepolycystic ovary syndrome cardiovascular risk insuline resistanceInsulin ResistancebusinessHyperandrogenismAnovulationPolycystic Ovary Syndrome
researchProduct

Regulated Proteolysis of RAGE and AβPP as Possible Link Between Type 2 Diabetes Mellitus and Alzheimer's Disease

2009

Epidemiological studies have linked type 2 diabetes mellitus (T2DM) with an increased risk of developing Alzheimer's disease (AD). In T2DM, the elevated blood glucose level promotes formation of advanced glycation end products (AGEs). The receptor for AGEs (RAGE) is a type I membrane-protein and is also able to import amyloid-beta (Abeta) from the blood across the blood-brain-barrier into the brain. Oligomeric Abeta peptides disturb synaptic function in the brain and are believed to contribute to the development of AD. Abeta peptides are released from the amyloid-beta protein precursor (AbetaPP) after sequential proteolysis by beta- and gamma-secretases but alpha-secretase-mediated cleavage…

medicine.medical_specialtyendocrine system diseasesProteolysisReceptor for Advanced Glycation End ProductsAmyloid beta-Protein PrecursorAlzheimer DiseaseGlycationInternal medicinemental disordersmedicineAnimalsHumansReceptors ImmunologicProtein precursorProtein kinase AReceptorAmyloid beta-Peptidesmedicine.diagnostic_testChemistryGeneral Neurosciencenutritional and metabolic diseasesGeneral MedicinePsychiatry and Mental healthClinical PsychologyCholesterolEndocrinologyDiabetes Mellitus Type 2EctodomainPeptide transportAmyloid Precursor Protein SecretasesGeriatrics and GerontologySignal transductionJournal of Alzheimer's Disease
researchProduct

Interaction of Diet/Lifestyle Intervention and TCF7L2 Genotype on Glycemic Control and Adiposity among Overweight or Obese Adults: Big Data from Seve…

2021

Objective . The strongest locus which associated with type 2 diabetes (T2D) by the common variant rs7903146 is the transcription factor 7-like 2 gene ( TCF7L2 ). We aimed to quantify the interaction of diet/lifestyle interventions and the genetic effect of TCF7L2 rs7903146 on glycemic traits, body weight, or waist circumference in overweight or obese adults in several randomized controlled trials (RCTs). Methods . From October 2016 to May 2018, a large collaborative analysis was performed by pooling individual-participant data from 7 RCTs. These RCTs reported changes in glycemic control and adiposity of the variant rs7903146 after dietary/lifestyle-related interventions in overweight or ob…

medicine.medical_specialtyendocrine system diseasesbusiness.industryComputer applications to medicine. Medical informaticsR858-859.7nutritional and metabolic diseasesOverweightlaw.inventionRandomized controlled triallawInternal medicineGenotypeLifestyle interventionMedicinemedicine.symptombusinessTCF7L2GlycemicHealth Data Science
researchProduct

Treatment of patients with essential hypertension and microalbuminuria.

1998

There has been increasing interest in the question of whether microalbuminuria can be used in the risk stratification of patients with essential hypertension. A cluster of cardiovascular and/or renal risk factors may be associated with microalbuminuria in hypertension. Despite this, prospective data about the potential role of microalbuminuria as a prognostic marker of cardiovascular and/or renal risk have been sparse and inconclusive until now. Blood pressure values have been considered the most important determinant of microalbuminuria in essential hypertension; however, hyperinsulinaemia--a metabolic component-was noted to be present in conjunction with high blood pressure. Furthermore, …

medicine.medical_specialtyendocrine system diseasesbusiness.industrynutritional and metabolic diseasesProspective dataurologic and male genital diseasesmedicine.diseaseDisease clusterEssential hypertensionfemale genital diseases and pregnancy complicationsSurgeryPharmacotherapyFelodipineInternal medicineRisk stratificationHypertensionmedicineDoxazosinAlbuminuriaHumansPharmacology (medical)MicroalbuminuriabusinessAntihypertensive Agentsmedicine.drugDrugs
researchProduct

Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.

2019

In general, both European and American clinical guidelines have addressed the management of atherogenic dyslipidaemia in an unconvincing and even superficial way, largely because of the available therapeutic limitations. Consequently, this type of dyslipidaemia is underdiagnosed, under-treated, and under-controlled. Given the recent presentation of the 2019 guidelines of the European Atherosclerosis Society and the European Society of Cardiology on the management of dyslipidaemias, it seems appropriate to examine its position with respect to atherogenic dyslipidaemia and/or its main components, the increase in triglyceride-rich lipoproteins, and the decrease of high-density lipoprotein chol…

medicine.medical_specialtyendocrine system diseaseschemistry.chemical_compoundTriglycerides/HDL CholesterolInternal medicineMedicineHumanscardiovascular diseasesTriglyceridesGeneral Environmental ScienceLipoprotein cholesterolDyslipidemiasbusiness.industryCholesterolCholesterol HDLGeneral Engineeringnutritional and metabolic diseasesAtherosclerosisEuropechemistryPractice Guidelines as TopicCardiologyEuropean atherosclerosis societyGeneral Earth and Planetary Scienceslipids (amino acids peptides and proteins)businessClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome

2014

Resistin is an adipocyte- and monocyte-derived cytokine which has been implicated in the modulation of insulin action, energy, glucose and lipid homeostasis. Resistin has been associated with insulin resistance and many of its known complications. As a molecular link between metabolic signals, inflammation, and vascular dysfunction, resistin can be proposed as playing a significant role in the heightened inflammatory state induced by metabolic stress linked to excessive caloric intake, thus contributing to the risk for metabolic syndrome (MetS), type 2 diabetes (T2DM), and cardiovascular diseases (CVD). In this review, we highlighted the role of resistin, as an inflammatory cytokine, in the…

medicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentInflammationType 2 diabetesModels BiologicalType 2 diabetemetabolic syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceAdipocyteInternal medicineDiabetes mellitusDrug DiscoverymedicineHumansResistin030304 developmental biologyMetabolic SyndromePharmacology0303 health sciencesbusiness.industryDrug Discovery3003 Pharmaceutical ScienceMedicine (all)Insulinnutritional and metabolic diseasesCardiovascular diseasemedicine.disease3. Good healthcardiovascular diseasesEndocrinologyDiabetes Mellitus Type 2chemistryCardiovascular Diseases030220 oncology & carcinogenesisImmunologyResistintype 2 diabetesInflammation MediatorsMetabolic syndromemedicine.symptombusinesshormones hormone substitutes and hormone antagonists
researchProduct

Disturbed Glucose Metabolism and Left Ventricular Geometry in the General Population

2021

Background: This study sought to investigate the prevalence and clinical outcome of left ventricular (LV) geometry in prediabetes and type 2 diabetes mellitus (T2DM) and the impact of glucose metabolism on the incidence of left ventricular hypertrophy (LVH). Methods: 15,010 subjects (35–74 years) of the population-based Gutenberg Health Study were categorized into euglycemia, prediabetes, and T2DM according to clinical and metabolic (HbA1c) information. Clinical outcome was assessed via structured follow-up. Results: The study comprised 12,121 individuals with euglycemia (81.6%), 1415 with prediabetes (9.5%), and 1316 with T2DM (8.9%). Prevalence of LVH increased from euglycemia (10.2%) ove…

medicine.medical_specialtyendocrine system diseasestype 2 diabetes mellitusPopulationprediabetesCarbohydrate metabolismleft ventricular concentric remodelingLeft ventricular hypertrophyArticleInternal medicineMedicineMass indexPrediabetescardiovascular diseaseseducationeducation.field_of_studybusiness.industryIncidence (epidemiology)Hazard ratioRType 2 Diabetes Mellitusnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseleft ventricular hypertrophyleft ventricular geometryCardiologyMedicinebusinessJournal of Clinical Medicine
researchProduct